Matinas BioPharma Holdings, Inc. (MTNB) Key Metrics
MTNB valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $2.3M
- Enterprise value
- $1.8M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 34.8
- Price / book
- 1.4 10-yr median 2.7
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 2.08
MTNB key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsMTNB valuation Price multiples at each fiscal year-end price.
MTNB returns How much profit the business earns on the capital it uses.
MTNB per-share figures Results divided by the shares outstanding at year-end.
MTNB financial health Debt, liquidity and how easily interest is covered.
MTNB efficiency & capital use Working capital cycle and where the cash goes.
MTNB valuation history
MTNB returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
MTNB debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
MTNB cash returned to shareholders
MTNB price vs earnings per share
MTNB key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $3.2M | $2.5M | $47.0M | $108.4M | $212.3M | $267.8M | — | — | — | — |
| Enterprise value | $562,840 | −$1.9M | $36.8M | $83.7M | $167.4M | $212.8M | — | — | — | — |
| Price / sales | — | — | 42.9 | 34.0 | — | — | — | — | — | — |
| Price / book | 0.7 | 0.3 | 2.4 | 3.0 | 4.0 | 4.2 | — | — | — | — |
| EV / sales | — | — | 33.6 | 26.3 | — | — | — | — | — | — |
| Earnings yield | −322.5% | −977.2% | −48.8% | −19.4% | −11.0% | −8.4% | — | — | — | — |
| Free cash flow yield | −218.6% | −640.1% | −33.0% | −18.5% | −7.3% | −6.5% | — | — | — | — |
| Dividend yield | — | — | — | — | 397.4% | 255.0% | — | — | — | — |
| Shareholder yield (dividends + buybacks) | — | — | — | 0.0% | 397.4% | 255.0% | — | — | — | — |
| Share price at fiscal year-end | $8.79 | $7.65 | $162.15 | $375.00 | $757.50 | $1,020.00 | $1,702.50 | $446.25 | $870.00 | $1,050.00 |
| Per share | ||||||||||
| Revenue per share | $0.00 | $0.00 | $3.78 | $11.03 | $0.12 | $0.60 | — | — | — | — |
| Earnings per share | −$28.35 | −$74.76 | −$79.20 | −$72.63 | −$83.08 | −$85.50 | — | — | — | — |
| Operating cash flow per share | −$19.21 | −$48.97 | −$52.74 | −$66.26 | −$54.32 | −$66.16 | — | — | — | — |
| Free cash flow per share | −$19.21 | −$48.97 | −$53.49 | −$69.35 | −$55.25 | −$66.18 | — | — | — | — |
| Cash per share | $10.96 | $22.45 | $47.49 | $99.67 | $177.07 | $223.52 | — | — | — | — |
| Book value per share | $13.23 | $23.40 | $66.44 | $126.74 | $187.32 | $242.76 | — | — | — | — |
| Tangible book value per share | $7.04 | $16.43 | $51.41 | $111.68 | $171.79 | $226.18 | — | — | — | — |
| Dividends per share | — | — | — | — | $3,010.30 | $2,600.89 | — | — | — | — |
| Capex per share | $0.00 | $0.00 | $0.75 | $3.09 | $0.93 | $0.02 | — | — | — | — |
| Debt per share | $3.71 | $8.92 | $12.28 | $14.27 | $16.78 | $14.28 | — | — | — | — |
| Shares outstanding | 365K | 324K | 290K | 289K | 280K | 263K | — | — | — | — |
| Change in shares outstanding | +12.5% | +12.0% | +0.2% | +3.2% | +6.7% | — | — | — | — | — |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | −166.6% | −180.7% | −82.1% | −47.1% | −40.1% | −46.4% | −70.6% | −105.0% | −173.7% | −114.9% |
| Return on invested capital (ROIC) | −204.2% | −260.1% | −178.9% | −199.0% | −238.6% | −208.9% | −220.0% | −299.5% | −381.8% | −215.8% |
| Return on assets (ROA) | −104.2% | −128.5% | −44.1% | −30.0% | −35.2% | −40.4% | −57.7% | −82.0% | −127.8% | −83.4% |
| Return on tangible assets | −209.1% | −233.6% | −110.6% | −28.2% | −40.9% | −33.7% | −48.4% | −90.3% | −153.8% | −139.1% |
| Free cash flow margin | — | — | — | −628.9% | — | — | — | — | — | — |
| Financial health | ||||||||||
| Total debt | $1.4M | $2.9M | $3.6M | $4.1M | $4.7M | $3.8M | $4.2M | $390,747 | $264,894 | $144,432 |
| Cash & short-term investments | $4.0M | $7.3M | $13.8M | $28.8M | $49.6M | $58.7M | $27.8M | $12.4M | $7.3M | $4.1M |
| Net debt | −$2.6M | −$4.4M | −$10.2M | −$24.7M | −$44.9M | −$54.9M | −$23.5M | −$12.1M | −$7.0M | −$4.0M |
| Debt / equity | 0.28 | 0.38 | 0.18 | 0.11 | 0.09 | 0.06 | 0.13 | 0.02 | 0.02 | 0.02 |
| Debt / assets | 0.19 | 0.23 | 0.14 | 0.05 | 0.08 | 0.05 | 0.11 | 0.02 | 0.02 | 0.01 |
| Current ratio | 2.79 | 3.01 | 5.93 | 8.06 | 11.73 | 17.25 | 9.66 | 4.61 | 3.58 | 3.16 |
| Quick ratio | 2.79 | 3.01 | 5.93 | 8.06 | 11.73 | 17.25 | 9.66 | 4.61 | 3.58 | 3.16 |
| Interest coverage | — | — | — | -6.8 | -17.0 | — | — | — | — | — |
| Working capital | $2.6M | $5.4M | $12.9M | $30.2M | $46.6M | $58.0M | $26.8M | $10.2M | $5.7M | $3.1M |
| Invested capital | $2.2M | $3.2M | $9.0M | $11.9M | $7.6M | $8.8M | $9.5M | $4.1M | $3.6M | $3.2M |
| Tangible asset value | $2.6M | $5.3M | $14.9M | $32.3M | $48.1M | $59.4M | $28.7M | $11.8M | $6.3M | $2.8M |
| Net current asset value | $1.7M | $3.0M | $9.7M | −$7.7M | $42.2M | $54.3M | $22.7M | $9.3M | $4.2M | $1.9M |
| Graham net-net per share | $4.44 | $6.88 | $27.26 | −$46.41 | $145.55 | $197.81 | — | — | — | — |
| Capital allocation | ||||||||||
| Dividends paid | — | — | — | — | $843.6M | $682.8M | $2.23B | $587.1M | $608.3M | $4.39B |
| Share buybacks (net) | — | — | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Capex / revenue | — | — | 19.9% | 28.0% | 789.0% | 3.6% | 451.6% | 447.5% | 629.4% | — |
| Capex / depreciation | 0.00 | 0.00 | 0.23 | 0.99 | 0.33 | 0.01 | 0.52 | 2.45 | 9.37 | 17.90 |
| Stock-based compensation / revenue | — | — | 451.5% | 164.0% | 13,007.1% | 2,883.0% | 3,323.9% | 3,200.9% | 2,403.3% | — |
| R&D / revenue | — | — | 1,322.0% | 523.1% | 44,190.9% | 9,068.8% | 12,509.0% | 5,668.0% | 6,019.6% | — |
| SG&A / revenue | — | — | 860.6% | 348.2% | 30,863.6% | 6,319.6% | 8,658.4% | 6,662.9% | 5,105.0% | — |
| Efficiency | ||||||||||
| Days sales outstanding | — | — | — | — | — | 1,498.4 | — | — | — | — |
| Days payables outstanding | 164.1 | 114.3 | 219.5 | 17.0 | 16.1 | 13.1 | 15.8 | 23.6 | 21.4 | 3,374.6 |
| Cash conversion cycle (days) | — | — | — | — | — | 1,485.3 | — | — | — | — |
| Receivables turnover | — | — | — | — | — | 0.24 | — | — | — | — |
| Payables turnover | 2.22 | 3.19 | 1.66 | 21.45 | 22.66 | 27.90 | 23.05 | 15.45 | 17.03 | 0.11 |
| Asset turnover | 0.00 | 0.00 | 0.02 | 0.05 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.00 |
| Average receivables | — | — | — | — | — | $650,000 | — | — | — | — |
| Average payables | $205,000 | $304,500 | $566,000 | $777,500 | $643,470 | $514,626 | $487,481 | $439,260 | $529,234 | $486,722 |
| Intangibles / total assets | 31.4% | 17.9% | 17.3% | 5.5% | 7.1% | 6.1% | 10.8% | 21.8% | 30.2% | 44.4% |
Computed from MTNB's annual financial statements (latest annual report filed March 31, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
MTNB valuation and financial ratios
Matinas BioPharma earned a return on equity of −166.6% and a return on invested capital of −204.2% in fiscal 2025. It ended the year with $1.4 million of debt and $4.0 million in cash and short-term investments, a net cash position of $2.6 million.
See the MTNB income statement, the MTNB chart for price history, or the MTNB stock overview for the latest quote and news.
MTNB key metrics FAQ
What is Matinas BioPharma's return on equity?
Matinas BioPharma's return on equity (ROE) was −166.6% in fiscal 2025: net income of -$10.3 million on average shareholders' equity of $6.2 million.
What is Matinas BioPharma's ROIC?
Matinas BioPharma's return on invested capital was −204.2% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Matinas BioPharma have?
Matinas BioPharma had total debt of $1.4 million at the end of fiscal 2025, a debt-to-equity ratio of 0.28 and more cash than debt.
What is Matinas BioPharma's free cash flow yield?
Matinas BioPharma generated -$7.0 million of free cash flow in fiscal 2025, a free cash flow yield of −218.6% on its market value at year-end ($3.2 million).
What is Matinas BioPharma's current ratio?
Matinas BioPharma's current ratio was 2.79 at the end of fiscal 2025: current assets were 2.79 times current liabilities.